Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

Archives of Toxicology

Volumn 89, Issue 8, 2015, Pages 1227-1240

  Suda, Kenichi ^a   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Acquired resistance; Cytotoxic chemotherapy; EGFR tyrosine kinase inhibitor; Molecular biomarkers; Personalized therapy

Indexed keywords

CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

BASIC RESEARCH; CANCER PROGNOSIS; CANCER RESISTANCE; CHEMOSENSITIVITY; DRUG MECHANISM; GENE MUTATION; HUMAN; IN VITRO STUDY; LUNG CANCER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84937968686     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1524-7     Document Type: Review

References (102)

1. Arcila ME, Oxnard GR, Nafa K et al (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17(5):1169–1180
2. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932–20937
3. Ceppi P, Volante M, Novello S et al (2006a) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17(12):1818–1825
4. Ceppi P, Volante M, Saviozzi S et al (2006b) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7):1589–1596
5. Chen Z, Liu X, Zhao J, Yang H, Teng X (2014) Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol 7(11):8039–8045
6. Christoph DC, Asuncion BR, Hassan B et al (2013) Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 8(1):19–30
7. Cuyun Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ (2014) A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res 6:437–449
8. D’Angelo SP, Janjigian YY, Ahye N et al (2012) Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 7(12):1815–1822
9. Dong X, Zhao X, Hao Y, Wei Y, Yin Q, Du J (2013) Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. Clin Lung Cancer 14(6):680–687
10. Engelman JA, Zejnullahu K, Gale CM et al (2007a) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67(24):11924–11932
11. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007b) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043
12. Ercan D, Xu C, Yanagita M et al (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2(10):934–947
13. Fang S, Wang Z, Guo J et al (2014) Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. OncoTargets Ther 7:1185–1193
14. Filipits M, Pirker R (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung cancer. 74(3):355–363
15. Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101–1110
16. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874
17. Gandara DR, Grimminger P, Mack PC et al (2010) Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 5(12):1933–1938
18. Giovannetti E, Mey V, Nannizzi S et al (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118
19. Han JY, Park K, Kim SW et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122–1128
20. Hotta K, Kiura K, Toyooka S et al (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2(7):632–637
21. Hu H, Pan Y, Li Y et al (2014) Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. OncoTargets Ther 7:1423–1437
22. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–354
23. Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24(1):54–59
24. Izar B, Sequist L, Lee M et al (2013) The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg 96(3):962–968
25. Janjigian YY, Park BJ, Zakowski MF et al (2011) Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 6(3):569–575
26. Jie L, Li XY, Zhao YQ et al (2014) Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: relationship between histologic subtypes, TITF-1/SP-a expressions and EGFR mutations. Pathol Res Pract 210(3):176–181
27. Kalikaki A, Koutsopoulos A, Hatzidaki D et al (2010) Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69(1):110–115
28. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19(13):3210–3218
29. Kim YH, Hirabayashi M, Togashi Y et al (2012) Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol 70(2):271–276
30. Kim YT, Seong YW, Jung YJ et al (2013) The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 8(2):171–178
31. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792
32. Kobayashi N, Toyooka S, Ichimura K et al (2008) Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol 3(7):704–710
33. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4(1):22–29
34. Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711
35. Li H, Xie L, Lai RS (2013) Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer. Mol Clin Oncol 1(1):195–199
36. Lim KH, Huang MJ, Liu HC, Kuo HT, Tzen CY, Hsieh RK (2007) Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Med Oncol 24(4):388–393
37. Lin MW, Wu CT, Shih JY, Chang YL, Yang PC (2014) Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas
38. Liu HP, Isaac Wu HD, Chang JW et al (2010) Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol 5(8):1175–1184
39. Liu WS, Zhao LJ, Pang QS, Yuan ZY, Li B, Wang P (2014) Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol 31(1):771
40. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139
41. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388
42. Mariano C, Bosdet I, Karsan A et al (2014) A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. Lung Cancer 83(1):73–77
43. Marks JL, Broderick S, Zhou Q et al (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3(2):111–116
44. Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817–1824
45. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128
46. Mizuuchi H, Suda K, Sato K, et al (2015) Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. PloS One 10(4):e0123901
47. Mochinaga K, Tsuchiya T, Nagasaki T et al (2014) High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non–small-cell lung cancer using 5-fluorouracil. Clinical Lung Cancer 15(2):136–144
48. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957
49. Nakamura, H, Saji, H, Shinmyo, T, et al. (2014) Association of IASLC/ATS/ERS histologic subtypes of lung adenocarcinoma with epidermal growth factor receptor mutations in 320 resected cases. Clin Lung Cancer 16(3):209–15
50. Ohashi K, Sequist LV, Arcila ME et al (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109(31):E2127–E2133
51. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317–323
52. Okuda K, Sasaki H, Dumontet C et al (2008) Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62(1):105–112
53. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991
54. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500
55. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306–13311
56. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73
57. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC (2012) The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev 9(3):144–155
58. Ren S, Chen X, Kuang P et al (2012) Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 118(22):5588–5594
59. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246
60. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20(21):4285–4291
61. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551
62. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98
63. Schmid-Bindert G, Wang Y, Jiang H et al (2013) EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients—a comparative study of three different minimal invasive sampling methods. PLoS One 8(10):e77948
64. Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science translational medicine. 3(75):75ra26
65. Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334
66. Shien K, Toyooka S, Yamamoto H et al (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 73(10):3051–3061
67. Shim HS, Lee da H, Park EJ, Kim SH (2011) Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 135(10):1329–1334
68. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y (2013) Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Medical oncology. 30(3):645
69. Sonobe M, Nakagawa M, Takenaka K et al (2007) Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol 95(1):63–69
70. Su KY, Chen HY, Li KC et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30(4):433–440
71. Suda K, Mitsudomi T (2013) PTEN—a molecule that cancers abuse to overcome their achilles heels. In: Ke Xu (ed) PTEN structure, mechanisms-of-action, role in cell signaling and regulation, 1st edn. Nova Science Publishers, New York, p 17
72. Suda K, Mitsudomi T (2014) Successes and limitations of targeted cancer therapy in lung cancer. Prog Tumor Res 41:62–77
73. Suda K, Mitsudomi T (2015) Racial differences in lung cancer genetics. J Thorac Oncol 10(2):230–231
74. Suda K, Onozato R, Yatabe Y, Mitsudomi T (2009) EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4(1):1–4
75. Suda K, Murakami I, Katayama T et al (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16(22):5489–5498
76. Suda K, Tomizawa K, Fujii M et al (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6(7):1152–1161
77. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T (2012a) Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 31(3–4):807–814
78. Suda K, Tomizawa K, Mizuuchi H et al (2012b) Genetic and prognostic differences of non-small cell lung cancer between elderly patients and younger counterparts. Aging Dis 3(6):438–443
79. Suda K, Sato K, Shimizu S et al (2014) Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. BioMed Res Int 2014:645681
80. Suehisa H, Toyooka S, Hotta K et al (2007) Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 25(25):3952–3957
81. Sun PL, Seol H, Lee HJ et al (2012) High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7(2):323–330
82. Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L (2014) Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol 12:148
83. Tabara K, Kanda R, Sonoda K et al (2012) Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One 7(7):e41017
84. Takano T, Fukui T, Ohe Y et al (2008) EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26(34):5589–5595
85. Takezawa K, Pirazzoli V, Arcila ME et al (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site egfrt790M mutation. Cancer Discov 2(10):922–933
86. Tseng JS, Yang TY, Chen KC et al (2014) Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma. OncoTargets Ther 7:799–805
87. Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77–88
88. Vilmar AC, Sorensen JB (2011) Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev 20(119):45–52
89. Weinstein IB (2002) Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science. 297(5578):63–64
90. Wu SG, Yang CH, Yu CJ et al (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72(3):333–339
91. Wu YL, Liam CK, Zhou C, Wu G (2013) First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): Interim analyses from the phase i, open-label, ENSURE study. J Thorac Oncol 8(Suppl. 2):s603 WCLC abstracts
92. Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222
93. Xu CW, Wang G, Wang WL et al (2015) Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer. Exp Ther Med 9(3):880–884
94. Yamashita F, Azuma K, Yoshida T et al (2013) Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS One 8(8):e71356
95. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G (2014) The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 98(2):453–458
96. Yang JC-H, Schuler MH, Yamamoto N et al (2012) LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30(suppl):7500 abstr LBA7500
97. Yang JC, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151
98. Yano S, Wang W, Li Q et al (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22):9479–9487
99. Yoshizawa A, Sumiyoshi S, Sonobe M et al (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8(1):52–61
100. Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247
101. Zhang Z, Lee JC, Lin L et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44(8):852–860
102. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742